|
Major Depressive Disorder
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Genetic Risk Variants Associated With Comorbid Alcohol Dependence and Major Depression.
|
29071344 |
2017 |
|
Sense of smell impaired
|
0.110 |
Biomarker
|
phenotype |
BEFREE |
SEMA3A and SEMA7A were screened by Sanger sequencing in altogether 50 Finnish HH patients (34 with Kallmann syndrome (KS; HH with hyposmia/anosmia) and 16 with normosmic HH (nHH)).
|
24522099 |
2014 |
|
Hypogonadotropic hypogonadism
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Sense of smell impaired
|
0.110 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Semaphorin 3A (Sema3A) restrain tumor growth and angiogenesis by partially reversing VEGF effects on tumor.
|
31148871 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Neuropilin-1 Ligand, Sema3A, Acts as a Tumor Suppressor in the Pathogenesis of Acute Leukemia.
|
30378769 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Interaction of Nrp-1 with its ligand semaphorin-3A inhibits migration and tumour-specific lytic function of cytotoxic T lymphocytes.
|
31350404 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that measurement of sema3A serum concentrations may be of use for the diagnosis and for the monitoring of malignancies of the bone marrow such as MM.
|
30102336 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Higher sema3A values were significantly correlated (P = 0.006) with presence of urothelial cancer, as determined by positive cystoscopy or urethroscopy and pathological biopsy.
|
29288007 |
2018 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In summary, mutant SEMA3A is a vascular normalizing agent that can be exploited to treat cancer and, potentially, other diseases characterized by pathological angiogenesis.
|
29794061 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
GBM patient-derived xenograft (PDX) models were generated to evaluate tumor inhibitory effect of anti-SEMA3A antibody in vivo.
|
29129044 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results indicate that miR-192-5p contributes to targeting SEMA3A in HCCLM3 cells, and this may be used as a target in targeted therapy and a marker for cancer behavior and prognosis.
|
26580097 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, overexpression of Sema3A in the tongue squamous cell carcinoma cell line SSC-9 resulted in significantly reduced angiogenesis and drastically suppressed tumor growth in mice.
|
28683823 |
2017 |
|
Alcohol-Related Disorders
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genetic Risk Variants Associated With Comorbid Alcohol Dependence and Major Depression.
|
29071344 |
2017 |
|
Alcohol-Induced Disorders
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Genetic Risk Variants Associated With Comorbid Alcohol Dependence and Major Depression.
|
29071344 |
2017 |
|
Waist Circumference
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Whole-Genome Sequencing Coupled to Imputation Discovers Genetic Signals for Anthropometric Traits.
|
28552196 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In human breast cancer specimens, we found that immunohistochemical levels of SEMA3A correlated with the expression of genes characteristic of M1 macrophages, CD8(+) T cells, and NK cells, while inversely correlating with established characters of malignancy.
|
27197153 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Animal studies indicated that Semaphorin 3A overexpression enhanced tumor growth and lung metastasis.
|
27351132 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results suggest that tumor cells decrease Sema3a mRNA expression in osteoblast in an mTORC1-dependent manner.
|
26865270 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our results indicate that SEMA3A serves as a tumor suppressor during HNSCC tumorigenesis and a new target for the treatment of HNSCC.
|
26755661 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor cell-derived SEMA3A restricted the proliferation of protumoral M2 macrophages but increased the proliferation of antitumoral M1, acting through the SEMA3A receptor neuropilin 1.
|
27197153 |
2016 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression levels of SEMA3A were lower in the cancer tissues with III/IV stage [the International Federation of Gynecology and Obstetrics (FIGO) stage], poor histological grade, lymph node metastasis and distant metastasis compared to that in the cancer tissues with I/II stage (FIGO), well histological grade, or without lymph node metastasis and distant metastasis (P<0.05).
|
25812535 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, SEMA3A has also been considered as a candidate tumor suppressor, since it is often downregulated in numerous types of cancer, including prostate cancer, breast cancer and glioma.
|
25812535 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Semaphorin3a (sema3a), a member of class 3 semaphorins, is a guidance protein that regulates angiogenesis, branching morphogenesis, axon growth, and cell migration, and has pleiotropic roles on organogenesis, immune response, and cancer.
|
24464477 |
2014 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on human tumor gene expression databases, HMGB1 was significantly inversely correlated with SEMA3A, suggesting that this mechanism may be more widely relevant in different cancer types.
|
24213571 |
2014 |